Patient-Derived Cancer Stem Cells Offer Diagnostic and Therapeutic Potential in Brain Cancer

John S. Kuo, MD, PhD, FAANS, FACS
Published: Wednesday, Mar 01, 2017
Carbone Cancer CenterJohn S. Kuo, MD, PhD, FAANS, FACS
John S. Kuo, MD, PhD, FAANS, FACS
Associate Professor,
Neurological Surgery
Director, Comprehensive
Brain Tumor Program
Chair, CNS Tumors Group
Carbone Cancer Center
Madison, WIDr. Catherine M. Diefenbach
More than a decade ago, cancer cells with stem-like properties were first identified in human solid tumors (eg, breast cancer, glioblastoma).1,2 Unlike cancer cell lines isolated from surgical specimens and grown in standard media, patient-derived cancer stem cells (CSCs) were defined by their ability to grow as non-adherent sphere cultures in stem cell media, to express progenitor markers and manifest multipotent differentiation, and to generate phenotypically diverse cancer cells in orthotopic xenografts with remarkably high efficiency.3

Many studies support the hypothesis that CSCs are therapeutically resistant cells that can cause tumor recurrence, implying that targeting CSCs could improve outcomes for incurable cancers such as the adult primary brain tumor glioblastoma multiforme (GBM).4 Compared with serum-cultured lines, CSC lines also retain more genetic similarity to patients’ tumors and generate patient-derived xenograft models for clinically relevant studies.5

Our brain tumor research group at the UW Carbone Cancer Center focuses on biological studies of patient-derived GBM CSCs, combined with analysis of patient-matched serum-cultured GBM and an annotated GBM tissue microarray (TMA), to identify clinically relevant biomarkers. Patientderived tumor lines and orthotopic xenografts are also valuable resources for in vitro and in vivo testing of novel agents and therapeutic strategies.

CSC Studies Yield Clinically Relevant Answers

Our observation that GBM CSCs can survive in minimal media without exogenous growth factors partly explained the failure of EGFR-targeted therapies for GBM, despite their efficacy for lung and breast cancer. The addition of EGFR inhibitors causes CSCs to rapidly upregulate and increase expression of other EGFR-related receptors such as HER2 and HER3, and multireceptor inhibition was required for therapeutic effect.6 We also characterized the genetic heterogeneity of GBMs by subgrouping CSC lines according to neural lineage markers, and identified cyclic nucleotide phosphodiesterase and cadherin-19 as new GBM biomarkers.7,8

Expression of these biomarkers was associated with less invasive CSC-derived xenografts and better survival of patients with GBM, showing the clinical relevance of CSC-identified tumor biomarkers. Differential microRNA (miR) screening of CSCs compared with normal neural stem cells identified miR-100 as a possible tumor suppressor in GBM, and initial results show promise for miR-100 pathway- based therapeutic strategies.9

GBM is difficult to treat due to cellular invasion and infiltration of surrounding brain tissue. We discovered that organized collagen in the tumor microenvironment is associated with less invasive xenografts and serves as a biomarker for improved patient survival on TMA analysis.10 Collagen is not abundantly expressed in the brain, whereas it is abundantly found in the rest of the body; in contrast, expression of organized collagen is a prometastatic signature for breast cancer and also is associated with worse survival.11 The discovery about tissue-dependent tumorigenic mechanisms could inform future therapeutic development.

Our CSC work also yielded insights for developing cancer therapeutics against ion channels that are aberrantly expressed in many cancers and are involved in tumor proliferation, survival, invasion, and angiogenesis. We analyzed the expression of Ether-à-go-go–related gene (hERG) potassium channels in patient-derived CSC cells and CSC-derived xenografts, and TMA analysis of patient GBM specimens. High hERG expression correlated with increased xenograft proliferation, and patients with higher hERG expression experienced worse survival. Inhibition of hERG also decreased CSC sphere growth and proliferation.

A promising finding from GBM TMA analysis showed that patients who incidentally received off-target hERG inhibitory drugs experienced improved survival, but only for the high hERG-expressing GBM patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication